Lippincott Pharmacology Practice Exam

Erythromycin and azithromycin are both macrolide antibiotics, but their spectrum of activity has important distinctions, particularly regarding their effectiveness against respiratory pathogens. Azithromycin is known for its improved pharmacokinetic properties and enhanced activity against specific respiratory pathogens, particularly Streptococcus pneumoniae and Haemophilus influenzae. These pathogens are common culprits in respiratory infections, and azithromycin's extended half-life allows it to be dosed less frequently and ensures better tissue penetration, leading to improved efficacy in treating respiratory infections.

In contrast, erythromycin has a narrower spectrum, particularly against certain gram-negative organisms. While both antibiotics can be used for similar infections, azithromycin’s enhanced activity against respiratory pathogens represents a significant clinical advantage in treating conditions such as community-acquired pneumonia or exacerbations of chronic obstructive pulmonary disease. This characteristic of azithromycin contributes to its often preferred use in clinical practice for respiratory infections where these pathogens are suspected.